Interferon α may be back on track to treat acute myeloid leukemia
暂无分享,去创建一个
[1] Z. Berneman,et al. Correction: Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential , 2014, PLoS ONE.
[2] E. Smits,et al. CD56 marks human dendritic cell subsets with cytotoxic potential , 2013, Oncoimmunology.
[3] G. Guillerm,et al. Pegylated interferon α2a induces complete remission of acute myeloid leukemia in a postessential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation , 2013, Annals of Hematology.
[4] Z. Berneman,et al. Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential , 2012, PloS one.
[5] R. Schreiber,et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.
[6] Z. Berneman,et al. Interferon-α in acute myeloid leukemia: an old drug revisited , 2011, Leukemia.
[7] Z. Berneman,et al. Induction of complete remission of acute myeloid leukaemia by pegylated interferon‐α‐2a in a patient with transformed primary myelofibrosis , 2010, British journal of haematology.
[8] W. Scherbaum,et al. IFN-α Skews Monocytes into CD56+-Expressing Dendritic Cells with Potent Functional Activities In Vitro and In Vivo1 , 2008, The Journal of Immunology.
[9] M. Wadhwa,et al. Continuous delivery of human type I interferons (α/β) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model , 2007 .
[10] M. Wadhwa,et al. Continuous delivery of human type I interferons (alpha/beta) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model. , 2007, Blood.
[11] R. Mesa,et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. , 2005, Blood.